Amgen to partner with Janssen in drug-combination study
Amgen plans to partner with Janssen Biotech to further assess the drug combination of KYPROLIS, developed by Amgen, and DARZALEX, developed by Janssen. Read More »
Amgen plans to partner with Janssen Biotech to further assess the drug combination of KYPROLIS, developed by Amgen, and DARZALEX, developed by Janssen. Read More »
The National Pharmaceutical Council Board of Directors has appointed Dr. Joshua Ofman as its new vice chairman. Read More »
Amgen's results of its Phase 3 coronary intravascular imaging trial, call GLAGOV, will be presented at the American Heart Association Scientific Sessions 2016. Read More »
Amgen's Phase 3 clinical trial to assess XGEVA compared to zoledronic acid has achieved its primary goal of proving to delay the time to the first skeletal-related event on-study for multiple myeloma patients. Read More »
Amgen's Phase 3 erenumab clinical trial has turned in positive results. Read More »
The U.S. Food and Drug Administration has approved Amgen’s AMJEVITA for the treatment of seven different inflammatory diseases. Read More »
Amgen recently reported top-line results of its Phase 3 CLARION trial that was designed to assess KYPROLIS (carfilzomib), melphalan and prednisone (KMP), Amgen's new investigational regimen, while comparing it to Velcade (bortezomib). Read More »
Cumberland Pharmaceuticals has announced that it has initiated a Phase II clinical program involving Portaban. Read More »
Amgen has announced that the data from studies involving romosozumab and Prolia will be presented at the Annual Meeting of American Society for Bone and Mineral Research (ASBMR) on Sept. 16-19 in Atlanta, Georgia. Read More »
Amgen and Servier last week announced that their cardiovascular collaboration has seen an advancement due to Servier deciding to exercise its option for the commercialization of omecamtiv mecarbil in Europe for chronic heart failure. Read More »
The decision by the FDA was done under accelerated approval with continued approval dependent on consequent trials verifying the clinical benefit of BLINCYTO. Read More »
Agreement gives Amgen global development and commercial rights to BI 836908 (AMG 420). Read More »
Adding Prolia to glucocorticoid therapy increases bone mineral density. Read More »
Will present 11 abstracts at the conference in Rome on Aug. 27-31. Read More »
Amgen and Advaxis has announced the finalization of a worldwide agreement for the development and commercialization of Advaxis’ ADXS-NEO, a novel, preclinical investigational immunotherapy developed for the treatment of cancer. Read More »
An advisory panel of the Federal Drug Administration (FDA) recently recommended approval of a medication manufactured by Amgen as a feasible alternative product to Humira, a brand created by AbbVie. Read More »
Change Healthcare SVP and General Manager to serve a two-year term on the committee. Read More »
Early relapsing patients treated with Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone (KRd) showed median PFS of 24.1 months. Read More »
Survey reveals that students learn best with hands-on experiments and field trips. Read More »
Cigna Corp. may receive additional price discounts from pharmaceutical companies should new cholesterol medications prove less effective than expected — a move marks a crucial step in a broader initiative to link the cost of medications to their efficacy. Read More »